Pages that link to "Q84747690"

The following pages link to Effectiveness and safety of tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, in a patient with refractory GI graft-versus-host disease (Q84747690):

Displaying 19 items.

• Interleukin-6 in Allogeneic Stem Cell Transplantation: Its Possible Importance for Immunoregulation and As a Therapeutic Target (Q33774610) (← links)
• Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levels (Q34624143) (← links)
• Anti–IL6-receptor-alpha (tocilizumab) does not inhibit human monocyte-derived dendritic cell maturation or alloreactive T-cell responses (Q35553632) (← links)
• Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity (Q35685660) (← links)
• Tocilizumab for the Treatment of Rheumatoid Arthritis and Other Systemic Autoimmune Diseases: Current Perspectives and Future Directions (Q35724900) (← links)
• Phenome-driven disease genetics prediction toward drug discovery. (Q35975061) (← links)
• Tocilizumab for steroid refractory acute graft-versus-host disease (Q36422339) (← links)
• Tocilizumab for the treatment of steroid refractory graft-versus-host disease (Q37026278) (← links)
• Role of STAT3 in regulatory T lymphocyte plasticity during acute graft-vs.-host-disease (Q37529686) (← links)
• Regulatory T Cells and IL-17-Producing Cells in Graft-Versus-Host Disease (Q37900645) (← links)
• Immunotherapeutic Implication of IL-6 Blockade (Q37965754) (← links)
• Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases (Q38058508) (← links)
• B-cell-mediated strategies to fight chronic allograft rejection (Q38175026) (← links)
• Inhibition of the interleukin-6 signaling pathway: a strategy to induce immune tolerance (Q38197519) (← links)
• A concise review on extracorporeal photochemotherapy: Where we began and where we are now and where are we going! (Q38440874) (← links)
• Successful treatment of acquired hemophilia A, complicated by chronic GVHD, with tocilizumab (Q45866414) (← links)
• Use of monoclonal antibodies in prophylaxis and treatment of acute and chronic graft-versus-host disease in 2011 (Q84749219) (← links)
• Harnessing GVHD by interleukin-6 receptor blockade (Q86128831) (← links)
• Tocilizumab promotes corneal allograft survival in rats by modulating Treg-Th17 balance (Q92073603) (← links)